HA
AKRO

HHLR Advisors’s Akero Therapeutics AKRO Stock Holding History

HHLR Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-273,002
Closed -$13.8M – 50
2023
Q3 		$13.8M Hold
273,002
– – 0.31% 30
2023
Q2 		$12.7M Sell
273,002
-22,500
-8% -$1.03M 0.27% 33
2023
Q1 		$11.3M Sell
295,502
-20,000
-6% -$892K 0.2% 39
2022
Q4 		$17.3M Sell
315,502
-364,498
-54% -$15.6M 0.37% 31
2022
Q3 		$23.2M Sell
680,000
-679,052
-50% -$10.4M 0.61% 27
2022
Q2 		$12.8M Sell
1,359,052
-100
-0% -$1.04K 0.28% 30
2022
Q1 		$19.3M Hold
1,359,152
– – 0.4% 28
2021
Q4 		$28.7M Sell
1,359,152
-181,313
-12% -$4.02M 0.44% 31
2021
Q3 		$34.4M Sell
1,540,465
-116,208
-7% -$2.63M 0.45% 34
2021
Q2 		$41.1M Hold
1,656,673
– – 0.42% 37
2021
Q1 		$48.1M Hold
1,656,673
– – 0.47% 31
2020
Q4 		$42.7M Hold
1,656,673
– – 0.34% 37
2020
Q3 		$51M Buy
1,656,673
+600,000
+57% +$21M 0.39% 31
2020
Q2 		$26.3M Buy
1,056,673
+165,472
+19% +$3.78M 0.24% 39
2020
Q1 		$18.9M Hold
891,201
– – 0.25% 37
2019
Q4 		$19.8M Buy
891,201
+141,777
+19% +$2.93M 0.25% 36
2019
Q3 		$17M Buy
749,424
+324,424
+76% +$7.55M 0.23% 44
2019
Q2 		$8.14M Buy
+425,000
New +$8.06M 0.18% 35

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HHLR Advisors's AKRO Position: Q4 2023 in Review

HHLR Advisors sold out of Akero Therapeutics (AKRO) in Q4 2023, closing a stake of 273,002 shares — an estimated $13.8M sold.

HHLR Advisors first reported a position in AKRO in Q2 2019 and held it in 18 quarters. The position peaked at $51M in Q3 2020. 157 funds tracked by Wall St. Rank hold AKRO as of Q4 2023.

  • HHLR Advisors reported no remaining Akero Therapeutics position as of Q4 2023 after selling out during the quarter.
  • HHLR Advisors sold 273,002 Akero Therapeutics shares in Q4 2023, an estimated $13.8M.
  • HHLR Advisors first reported a position in Akero Therapeutics in Q2 2019 and held it in 18 quarters.
  • HHLR Advisors's Akero Therapeutics position peaked at $51M in Q3 2020.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2023.

Based on HHLR Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.